jrnl7477

Publication Venue For

  • Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.  18:536-542. 2019
  • Colocolonic intussusception in an adult cystic fibrosis patient.  18:e11-e13. 2019
  • Abnormal pro-gly-pro pathway and airway neutrophilia in pediatric cystic fibrosis 2019
  • An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB) 2019
  • CFTR modulator theratyping: Current status, gaps and future directions.  18:22-34. 2019
  • Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.  18:102-109. 2019
  • Systemic levels of anti-PAD4 autoantibodies correlate with airway obstruction in cystic fibrosis 2019
  • Development and electronic validation of the revised Cystic Fibrosis Questionnaire (CFQ-R Teen/Adult): New tool for monitoring psychosocial health in CF.  17:672-679. 2018
  • Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis.  17:57-63. 2018
  • Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis 2018
  • Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis.  17:64-70. 2018
  • A multiple reader scoring system for Nasal Potential Difference parameters.  16:573-578. 2017
  • Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.  16:592-599. 2017
  • Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.  16:600-606. 2017
  • Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.  16:371-379. 2017
  • Applying recent advances in the science of CFTR-based therapeutics to improve outcomes in patients with cystic fibrosis 2017
  • Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.  16:24-29. 2017
  • Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.  15:227-233. 2016
  • Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.  15:67-73. 2016
  • Physical activity assessment in cystic fibrosis: A position statement.  14:e25-e32. 2015
  • Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.  14:219-227. 2015
  • Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.  14:228-236. 2015
  • Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis.  13:164-171. 2014
  • Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data.  13:139-147. 2014
  • ESCF care guidelines beyond Europe.  13:359-360. 2014
  • Evaluating the predictive ability of sweat chloride.  13:118. 2014
  • Marked repression of CFTR mRNA in the transgenic Cftrtm1kth mouse model.  13:351-352. 2014
  • Spiritual coping predicts 5-year health outcomes in adolescents with cystic fibrosis 2014
  • Spiritual coping predicts 5-year health outcomes in adolescents with cystic fibrosis.  13:593-600. 2014
  • Innate immunity in cystic fibrosis lung disease.  11:363-382. 2012
  • Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation.  11:40-45. 2012
  • Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis.  8:193-197. 2009
  • Bioelectric effects of quinine on polarized airway epithelial cells.  6:351-359. 2007
  • Assessment of CFTR localisation in native airway epithelial cells obtained by nasal brushing.  3:43-48. 2004
  • Gene delivery systems - Gene therapy vectors for cystic fibrosis.  3:203-212. 2004